“We believe that more than one vaccine will be needed to address this global pandemic and we are working with partners around the world to do so,” said GSK Global Vaccines President Roger Connor. Booster shotExperts have predicted that a successful vaccine will take more than a year to develop. AstraZeneca and Oxford University’s viral vector approach, where harmless viruses instruct human cells to make virus-like proteins, also needs no adjuvants. The United States last week secured almost a third of the first 1 billion doses planned for AstraZeneca’s experimental Covid-19 vaccine by pledging up to $1.2 billion. On Thursday GSK said that making its adjuvant available to the world’s poorest countries will be a key part of its efforts.

Source: Dhaka Tribune May 29, 2020 03:33 UTC